Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lü, et al.
The Innovation (2023) Vol. 4, Iss. 3, pp. 100413-100413
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

PROTAC technology: From drug development to probe technology for target deconvolution
Si Yan, Guangshuai Zhang, Wei Luo, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116725-116725
Closed Access | Times Cited: 19
BRD4-targeted photodegradation nanoplatform for light activatable melanoma therapy
Shiman Lu, Zhaoqing Shi, Chendi Ding, et al.
Biomaterials (2025) Vol. 317, pp. 123101-123101
Closed Access | Times Cited: 2
Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response
Hannah L. Chang, Blake Schwettmann, Heather L. McArthur, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 18
Open Access | Times Cited: 37
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
Zhifeng Zou, Lei Yang, Hui-Jun Nie, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 8, pp. 1740-1751
Closed Access | Times Cited: 14
Repurposing AS1411 for constructing ANM-PROTACs
Xuekun Fu, Jin Li, Xinxin Chen, et al.
Cell chemical biology (2024) Vol. 31, Iss. 7, pp. 1290-1304.e7
Closed Access | Times Cited: 10
Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation
Ying Wang, Tianzi Wei, Man Zhao, et al.
PLoS Biology (2024) Vol. 22, Iss. 5, pp. e3002550-e3002550
Open Access | Times Cited: 8
Identification of PLAC1 as a prognostic biomarker and molecular target in clear cell renal cell carcinoma
Ying Kong, Zongming Jia, Yizhang Sun, et al.
Cellular Signalling (2025) Vol. 127, pp. 111606-111606
Open Access | Times Cited: 1
Targeting autophagy drug discovery: Targets, indications and development trends
Mengjia Jiang, Wayne Wu, Zijie Xiong, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116117-116117
Closed Access | Times Cited: 7
High‐Throughput Miniaturized Synthesis of PROTAC‐Like Molecules
Ye Tian, Maximilian Seifermann, Liana Bauer, et al.
Small (2024) Vol. 20, Iss. 26
Closed Access | Times Cited: 6
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 14
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 494-494
Open Access | Times Cited: 5
Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy
Rajeshwari Meli, Osman Aksoy, Sonia Vallet, et al.
Expert Opinion on Therapeutic Targets (2025)
Closed Access
Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
Qiuzhi Zhou, Weixia Wang, Chunchu Deng
Molecular Neurobiology (2025)
Open Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumors
Jaya Aakriti, Megh Pravin Vithalkar, Swastika Maity, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Open Access
Differential analysis of Cereblon neosubstrates in rabbit embryos using targeted proteomics
Joel D. Federspiel, Natasha R. Catlin, William S Nowland, et al.
Molecular & Cellular Proteomics (2024) Vol. 23, Iss. 7, pp. 100797-100797
Open Access | Times Cited: 3
Supramolecular artificial Nano-AUTACs enable tumor-specific metabolism protein degradation for synergistic immunotherapy
Yazhen Wang, Lianyi Yang, C. Yan, et al.
Science Advances (2024) Vol. 10, Iss. 25
Open Access | Times Cited: 3
Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC)
Jianchao Zhang, Xiao Chen, Congli Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 13666-13680
Closed Access | Times Cited: 2
Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy
Yerim Jin, Yeongju Lee
ChemMedChem (2024) Vol. 19, Iss. 23
Open Access | Times Cited: 2
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity
Judith Lind, Osman Aksoy, Michaela Prchal‐Murphy, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Recent advances in dual PROTACs degrader strategies for disease treatment
Jianyu Liu, Yanzhuo Liu, Jiao Tang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116901-116901
Closed Access | Times Cited: 2
PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
Caterina Mancarella, Andrea Morrione, Katia Scotlandi
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16346-16346
Open Access | Times Cited: 6
Discovery of Alkenyl Oxindole as a Novel PROTAC Moiety for Targeted Protein Degradation via CRL4DCAF11Recruitment
Ying Wanga, Tianzi Wei, Man Zhao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top